Complex of 9-nitro-camptothecin in hydroxypropyl-β-cyclodextrin: In vitro and in vivo evaluation

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 116-121

  Jiang, Ye ^a   Sha, Xianyi ^a   Zhang, Wei ^a   Fang, Xiaoling ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

9 Nitro camptothecin; Dissolution; Freeze drying; Hydroxypropyl cyclodextrin; Pharmacokinetic studies; Stability

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; GAMMA CYCLODEXTRIN; GLUCOSYL BETA CYCLODEXTRIN; LACTONE; METHYL BETA CYCLODEXTRIN; RUBITECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; RAT; TEMPERATURE SENSITIVITY; THERMODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; CAMPTOTHECIN; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FREEZE DRYING; HALF-LIFE; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TEMPERATURE;

EID: 77955980868     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.012     Document Type: Article

References (18)

1. Chen J., Ping Q.N., Guo J.X., Chu X.Z., Song M.M. Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev. Ind. Pharm. 2006, 32:719-726.
2. Chen J., Ping Q.N., Guo J.X., Liu M.L., Cai B.C. Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-nitrocamptothecin in rats. Int. J. Pharm. 2007, 340:29-33.
3. Dadashzadeh S., Derakhshandeh K., Shirazi F.H. 9-Nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats. Anticancer Drug 2008, 19:805-811.
4. Gao J.M., Ming J., He B., Gu Z.W., Zhang X.D. Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(ethylene glycol)-poly(d,l-lactide) micelles. Biomed. Mater. 2008, 3:13-20.
5. Haglof K.J., Popa E., Hochster H.S. Recent developments in the clinical activity of topoisomerase-1 inhibitors. Update Cancer Therap. 2006, 1:117-145.
6. Han X., Liu J., Liu M., Xie C., Zhan C.Y., Gu B., Liu Y., Feng L.L., Lu W.Y. 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int. J. Pharm. 2009, 372:125-131.
7. Higguchi T., Lach J.L. Investigation of some complexes formed in solution by caffeine. J. Am. Pharm. Assoc. 1954, 43:349-354.
8. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86:147-162.
9. Kang J., Kumar V., Yang D., Chowdhury P.R., Hohl R.J. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur. J. Pharm. Sci. 2002, 15:163-170.
10. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
11. Loftsson T., Duchene D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007, 329:1-11.
12. Lu J.L., Wang J.C., Zhao S.X., Liu X.Y., Zhao H., Zhang X., Zhou S.F., Zhang Q. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur. J. Pharm. Biopharm. 2008, 69:899-907.
13. Maragos S., Archontaki H., Macheras P., Valsami G. Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel. AAPS PharmSciTech 2009, 10:1444-1451.
14. Sætern A., Nguyen N.B., Bauer-Brandl A., Brandl M. Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on solubility of camptothecin. Int. J. Pharm. 2004, 284:61-68.
15. Szejtli J. Past, present, and future of cyclodextrin research. Pure Appl. Chem. 2004, 76:1825-1845.
16. Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 1999, 36:17-28.
17. Verschraegen C.F., Natelson E.A., Giovanella B.C., Kavanagh J.J., Kudelka A.P., Freedman R.S., Edwards C.L., Ende K., Stehlin J.S. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drug 1998, 9:36-44.
18. Zhang L.J., Xing B., Wu J., Xu B., Fang X.L. Biodistribution in mice and severity of damage in rat lungs following pulmonary delivery of 9-nitrocamptothecin liposomes. Pulm. Pharmacol. Ther. 2008, 21:239-246.